Reduced effectiveness of long-term interferon-β treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study
- 1 November 2007
- journal article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 13 (9) , 1127-1137
- https://doi.org/10.1177/1352458507080468
Abstract
Multiple sclerosis (MS) patients treated with interferon-beta (IFN-β) often form anti-IFN-β antibodies accompanied by a reduction in IFN-β bioavailability. The clinical effect of these antibodies remains controversial. MS patients in British Columbia, Canada, must be diagnosed and evaluated annually by neurologists in an MS clinic in order to be reimbursed for their IFN-β prescriptions. We have identified at the UBC MS clinic a cohort of 262 patients, each having been treated with a single IFN-β preparation more than three years, some for nearly a decade. Of 119 patients treated with Betaseron® (IFN-β1b), 18 (15.1%) were neutralizing antibody positive (NAb+) at the time of the study, whereas of 131 treated with subcutaneous Rebif® (IFN-β1a SC), 16 (12.2%) were NAb+, but none of 12 treated with intramuscular Avonex ® (IFN-β1a) had detectable neutralizing antibodies. During the first two years of treatment, the relapse rate was significantly reduced from pre-treatment rates ( P < 0.001) and appeared to be unaffected by the subsequent NAb status. However, the relapse rates in the NAb+ patients were significantly greater than in the NAb— patients during years 3 ( P < 0.010) and 4 ( P < 0.027). Betaseron ®-treated NAb+ patients tended to have more relapses than NAb — patients during year 3 and this almost reached significance ( P = 0.056) but their relapse rate did not differ in year 4 and later. In contrast, Rebif ®-treated NAb+ patients tended to have more relapses in year 3 than Rebif ® -treated NAb — patients ( P = 0.074), but in year 4 they clearly ( P = 0.009) had more relapses than Rebif ®-treated NAb — patients. There was no convincing effect on progression of disability in any group. Multiple Sclerosis 2007; 13: 1127—1137. http://msj.sagepub.comKeywords
This publication has 28 references indexed in Scilit:
- Guidelines on use of anti‐IFN‐β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN‐β antibodies in multiple sclerosisEuropean Journal of Neurology, 2005
- Neutralizing antibodies reduce the efficacy of βIFN during treatment of multiple sclerosisNeurology, 2004
- Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1bNeurology, 2003
- Mapping of IFN-β Epitopes Important for Receptor Binding and Biologic Activation: Comparison of Results Achieved Using Antibody-Based Methods and Alanine Substitution MutagenesisJournal of Interferon & Cytokine Research, 2001
- The Neutralization of Interferons by Antibody. II. Neutralizing Antibody Unitage and Its Relationship to Bioassay Sensitivity: The Tenfold Reduction UnitJournal of Interferon & Cytokine Research, 2001
- The Neutralization of Interferons by Antibody. I. Quantitative and Theoretical Analyses of the Neutralization Reaction in Different Bioassay SystemsJournal of Interferon & Cytokine Research, 2001
- PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MSNeurology, 2001
- The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1bNeurology, 1999
- Development of Neutralizing Antibodies in Patients with Relapsing-Remitting Multiple Sclerosis Treated with IFN-β1aJournal of Interferon & Cytokine Research, 1998
- Interferon beta‐lb in the treatment of multiple sclerosisNeurology, 1995